Literature DB >> 4037774

Pharmacokinetic evaluation of cefoperazone in infants.

M Varghese, A J Khan, K Kumar, W Rosenfeld, H A Schaeffer, H E Evans.   

Abstract

The pharmacokinetics of cefoperazone were evaluated in 25 infants (mean age, 26 days) after intramuscular and intravenous routes of administration. The levels in blood that were achieved were severalfold higher than those required to inhibit common pathogens. The mean half-life of 240 min was one-half of that observed in 1- to 2-day-old infants but about twice that seen in adults. Further evaluation is needed to study the efficacy of the drug in infants and children.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 4037774      PMCID： PMC176329          DOI： 10.1128/AAC.28.1.149

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

1.  Comparative pharmacokinetics of cefoperazone, cefotaxime, and moxalactam.

Authors:  B Kemmerich; H Lode; G Belmega; T Jendroschek; K Borner; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1983-03       Impact factor: 5.191

2.  A clinical trial with cefoperazone in pneumonia and pyelonephritis.

Authors:  S C Park; J H Lee; D H Lee; S Y Kim; Y H Kim; C H Park; S E Seok; Y K Lee; B C Chung; E S Sohn
Journal:  Drugs       Date:  1981       Impact factor: 9.546

3.  Cefoperazone (T-1551), a new semisynthetic cephalosporin: comparison with cephalothin and gentamicin.

Authors:  R N Jones; P C Fuchs; A L Barry; T L Gavan; H M Sommers; E H Gerlach
Journal:  Antimicrob Agents Chemother       Date:  1980-04       Impact factor: 5.191

4.  Cefoperazone pharmacokinetics in preterm infants.

Authors:  J A Bosso; G M Chan; J M Matsen
Journal:  Antimicrob Agents Chemother       Date:  1983-03       Impact factor: 5.191

5.  Pharmacokinetics of cefoperazone in full-term and premature neonates.

Authors:  W N Rosenfeld; H E Evans; R Batheja; R C Jhaveri; K Vohra; A J Khan
Journal:  Antimicrob Agents Chemother       Date:  1983-06       Impact factor: 5.191

6.  Potential value of cefoperazone in bacterial meningitis: experimental studies.

Authors:  D T Durack; J R Perfect
Journal:  Drugs       Date:  1981       Impact factor: 9.546

7.  Worldwide clinical experience with cefoperazone.

Authors:  A U Gerber; W A Craig
Journal:  Drugs       Date:  1981       Impact factor: 9.546

Review 8.  Cefoperazone: A review of its in vitro antimicrobial activity, pharmacological properties and therapeutic efficacy.

Authors:  R N Brogden; A Carmine; R C Heel; P A Morley; T M Speight; G S Avery
Journal:  Drugs       Date:  1981-12       Impact factor: 9.546

9.  Pharmacokinetics of cefoperazone in normal volunteers and subjects with renal insufficiency.

Authors:  W K Bolton; W M Scheld; D A Spyker; M A Sande
Journal:  Antimicrob Agents Chemother       Date:  1981-05       Impact factor: 5.191

10.  Cefoperazone in Klebsiella meningitis: a case report.

Authors:  R B Ellis-Pegler; S D Lang
Journal:  Drugs       Date:  1981       Impact factor: 9.546
  10 in total
  3 in total

1.  Interspecies scaling for the prediction of drug clearance in children: application of maximum lifespan potential and an empirical correction factor.

Authors:  Iftekhar Mahmood
Journal:  Clin Pharmacokinet       Date:  2010-07       Impact factor: 6.447

Review 2.  Clinical Pharmacokinetics of Penicillins, Cephalosporins and Aminoglycosides in the Neonate: A Review.

Authors:  Gian Maria Pacifici
Journal:  Pharmaceuticals (Basel)       Date:  2010-08-12

Review 3.  Evaluation of evidence for pharmacokinetics-pharmacodynamics-based dose optimization of antimicrobials for treating Gram-negative infections in neonates.

Authors:  Nusrat Shafiq; Samir Malhotra; Vikas Gautam; Harpreet Kaur; Pravin Kumar; Sourabh Dutta; Pallab Ray; Nilima A Kshirsagar
Journal:  Indian J Med Res       Date:  2017-03       Impact factor: 2.375
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.